Medtronic PLC vs Tenet Healthcare Corporation — how do they compare? Medtronic PLC trades at $83.48 (market cap $106.50B), while Tenet Healthcare Corporation trades at $194 (market cap $16.79B). The key difference: Medtronic PLC is far larger — about 6.3× Tenet Healthcare Corporation's market cap, and Medtronic PLC pays a 3.46% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| MDT | THC | |
|---|---|---|
Market Cap | $106.50B | $16.79B |
Sector | Health | Health |
52-Week High | $105.35 | $244.80 |
52-Week Low | $73.75 | $148.38 |
Enterprise Value | $125.24B | $27.03B |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a neutral technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.82 exceeding expectations of $4.17. Valuation metrics appear attractive with a P/E of 10.14 and P/S of 0.79, while profitability remains robust with 82.47% gross margins and 37.87% ROE. Recent news highlights the company's expanding outpatient footprint through USPI as a key growth driver.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $235.88 price target representing 21% upside potential. The company's solid earnings momentum and defensive healthcare positioning during market volatility provide stability. Key risks include execution challenges in outpatient expansion and potential regulatory headwinds affecting hospital operations. Cash flow trends show improvement with projected net cash flow narrowing from -$136M in 2025 to -$32M in 2026.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →